6.4.5.1.2.1. target volume, dose, toxicity. various attempts define common outlines ‘clinical target volumes‘ pn0 pca organs risk normal tissue complications . however, given variations techniques dose-constraints, satisfactory consensus yet achieved. benefit biochemical pfs mfs reported patients receiving whole pelvis srt (± adt) advantages must weighed possible side effects . supported data spporttrial (nrg oncology/rtog 0534 spport) remains controversial . optimal srt dose well defined. least 64 gy prostatic fossa (± base svs, depending pathological stage rp) . sr, pre- srt psa level srt dose correlated bcr, showing relapse-free survival decreased 2.4% per 0.1 ng/ml psa improved 2.6% per gy, suggesting treatment dose 70 gy administered lowest possible psa level . combination pt stage, margin status isup grade group psa srt seems define risk biochemical progression, metastasis overall mortality . study 894 node-negative pca patients, doses ranging 64 > 74 gy assigned twelve risk groups defined pre-srt psa classes < 0.1, 0.1–0.2, 0.2–0.4, > 0.4 ng/ml isup grade group < 1 vs. 2/3 vs. > 4 . updated stephenson nomograms incorporate srt adt doses predictive factors biochemical failure distant metastasis . two rct’s published (table 6.4.6). intensity-modulated radiation therapy plus igrt used 57% patients sakk-trial patients chinese trial . patient psma pet/ct randomisation. primary endpoint trials ‘freedom biochemical progression’, significantly improved higher doses. however, chinese trial subgroup analysis showed significant improvement endpoint patients gleason 8-10 tumours (79.7% vs. 55%, p = 0.049) . trial, patients treated art srt number patients relatively small (n = 144). time seems difficult draw final conclusions optimal total rt-dose longer follow-up awaited. table 6.4.6: randomised trials investigating dose escalation srt without adt without pet-ct trialnpca conditionradiotherapydosefollow-up (median)outcomeresultssakk 09/10trial, 2021350pt2a-3br0 – r1pn0 cn0psa post opundetectable(< 0.1 ng/ml)or persistent(> 0.1 ng/ml < 0.4 ng/ml)64 gy vs.70 gyno adt allowedvmat+ igrt: 57%3-d planning: 43%6.2 yr.primary endpoint:ffbp6 yr. ffbp:62% vs. 61%os: differencelate side effects:gi grade 2:7.3% vs. 20%gi grade 3:4.2% vs. 2.3%p ≥ grade 2/3:0.009phase-iii-trialqi x, et al.,2020 144art: 33%srt: 67%pt2-4r0-r1pn0 cn0med. psa pre-rt: 0.2 ng/ml66 gy vs.72 gyall patientsvmat+ igrtno adt allowedhigh risk(pt3-4, gs: 8-10,psa>20 ng/ml):whole pelvis rt:126 (87.5%)49 mo.primary endpoint:ffbp4 yr. ffbp:75.9% vs. 82.6%(p > 0.05)high risk (gs: 8–10):55.7% vs. 79.7%p < 0.049)late side effects:gi + gu grade 2p > 0.05no grade 3 adt = androgen deprivation therapy; art = adjuvant radiotherapy; ffbp = freedom biochemical failure; gi = gastro-intestinal; gu = genito-urinary; gy = gray; igrt = image guided radiotherapy; mo = month; n = number patients; psa = prostate-specific antigen; rt = radiotherapy; srt = = year; vs. = versus; vmat = volumetric arc radiation therapy. salvage rt associated toxicity. one report 464 srt patients receiving median 66.6 (max. 72) gy, acute grade 2 toxicity recorded 4.7% gi gu tract. two men late grade 3 reactions gi tract, overall, severe gu tract toxicity observed. late grade 2 complications occurred 4.7% (gi tract) 4.1% (gu tract), respectively, 4.5% patients developed moderate urethral stricture . rct dose escalation srt (n = 350), acute grade 2 3 gu toxicity observed 13.0% 0.6%, respectively, 64 gy 16.6% 1.7%, respectively, 70 gy. gastro-intestinal tract grades 2 3 toxicity occurred 16.0% 0.6%, respectively, 64 gy, 15.4% 2.3%, respectively, 70 gy . late grade 2 3 gi toxicity significantly increased higher doses without significant differences qol. study, however, rectal wall dose constraints rather permissive 44% patients outdated 3-d-techniques used . dose escalation 72 gy and/or median 76 gy, rate severe side effects, especially gu symptoms, clearly increases, even newer planning treatment techniques . particular, compared 3d-crt, imrt associated reduction grade 2 gi toxicity 10.2 1.9% (p = 0.02) effect relatively high level gu toxicity shown (5-year, 3d-crt 15.8% vs. imrt 16.8%) . however, rct comparing 66 gy 72 gy patients imrt plus igrt (n = 144), significant differences gi gu-toxicity demonstrated . median salvage imrt dose 76 gy however, 5-year risk grade 2–3 toxicity rose 22% gu 8% gi symptoms, respectively . doses least 64 gy 72 gy patients without pet/ct recommended .